Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cerevel Therapeutics Holdings Inc

Current price
41.31 USD -0.29 USD (-0.70%)
Last closed 41.7 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 591 673 856 USD
Yield for 12 month +60.12 %
21.11.2021 - 28.11.2021

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. Address: 222 Jacobs Street, Cambridge, MA, United States, 02141

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

43.4 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-5 627 000 USD

Last Year

-4 903 000 USD

Current Quarter

-1 504 000 USD

Last Quarter

-1 449 000 USD

Key Figures CERE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -441 638 016 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -24.73 %
PEG Ratio
Return On Equity TTM -72.44 %
Wall Street Target Price 43.4 USD
Revenue TTM
Book Value 3.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -2.67 USD
Diluted Eps TTM -2.67 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CERE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CERE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:1
Payout Ratio
Last Split Date 28.10.2020
Dividend Date

Stock Valuation CERE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -16.7649
Price Book MRQ 11.2787

Financials CERE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CERE

For 52 weeks

19.59 USD 43.59 USD
50 Day MA 41.94 USD
Shares Short Prior Month 6 962 845
200 Day MA 32.33 USD
Short Ratio 7.56
Shares Short 9 622 787
Short Percent 11.15 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics